0

Journal Articles

in Cardiovascular Disease Prevention
 1-20 of 147 Articles
RESEARCH LETTER |  June 17, 2013 ONLINE FIRST
ω-3 Fatty Acid Supplements for Secondary Prevention of Cardiovascular Disease: From “No Proof of Effectiveness” to “Proof of No Effectiveness”
Andrea Messori, PharmD; Valeria Fadda, PharmD; Dario Maratea, PharmD; et al.
JAMA Intern Med. 2013;():1-2. doi:10.1001/jamainternmed.2013.6638.
Editor's Correspondence |  June 10, 2013
Noncommunicable Diseases in Developing Countries: Focus on Research Capacity Building
Ayodele Odutayo, BHSc; Naheed Hirji, BASc
JAMA Intern Med. 2013;173(11):1031-1032. doi:10.1001/jamainternmed.2013.356.
Research Letters |  May 13, 2013
Rapid Assessment of Cardiovascular Risk Among Users of Smoking Cessation Drugs Within the US Food and Drug Administration's Mini-Sentinel Program
Sengwee Toh, ScD; Meghan A. Baker, MD, ScD; Jeffrey S. Brown, PhD; et al.
JAMA Intern Med. 2013;173(9):817-819. doi:10.1001/jamainternmed.2013.3004.
INCLUDES: , Supplemental Content
Original Investigation |  April 22, 2013
Dietary and Supplemental Calcium Intake and Cardiovascular Disease Mortality:  The National Institutes of Health–AARP Diet and Health Study
Qian Xiao, PhD; Rachel A. Murphy, PhD; Denise K. Houston, PhD; et al.
JAMA Intern Med. 2013;173(8):639-646. doi:10.1001/jamainternmed.2013.3283.
INCLUDES: , Supplemental Content
Invited Commentary |  April 22, 2013
Are Calcium Supplements Harmful to Cardiovascular Disease?:  Comment on “ Dietary and Supplemental Calcium Intake and Cardiovascular Diseases Mortality: The National Institutes of Health–AARP Diet and Health Study”
Susanna C. Larsson, PhD
JAMA Intern Med. 2013;173(8):647-648. doi:10.1001/jamainternmed.2013.3769.
Research Letters |  April 08, 2013
A National Survey of the Treatment of Hyperlipidemia in Primary Prevention
Michael E. Johansen, MD; Katherine J. Gold, MD, MSW, MS; Ananda Sen, PhD; et al.
JAMA Intern Med. 2013;173(7):586-588. doi:10.1001/jamainternmed.2013.2797.
INCLUDES: , Supplemental Content
Research Letters |  April 08, 2013
Benefits of Participation in Diabetes Group Visits After Trial Completion
George L. Jackson, PhD, MHA; David Edelman, MD, MHS; Maren K. Olsen, PhD; et al.
JAMA Intern Med. 2013;173(7):590-592. doi:10.1001/jamainternmed.2013.2803.
INCLUDES: , Supplemental Content
Research Letters |  February 11, 2013
Effect of Patient Navigation on Enrollment in Cardiac Rehabilitation
Lisa Benz Scott, PhD; Shannon Gravely, PhD; Thomas R. Sexton, PhD; et al.
JAMA Intern Med. 2013;173(3):244-246. doi:10.1001/2013.jamainternmed.1042.
Invited Commentary |  February 11, 2013
Bending the Curve Toward Increased Use of Generic Drugs:  Comment on “When Choosing Statin Therapy”
Brian K. Alldredge, PharmD; Steven R. Kayser, PharmD
JAMA Intern Med. 2013;173(3):233-234. doi:10.1001/jamainternmed.2013.1777.
Research Letters |  December 10, 2012
Body Mass Index vs Cholesterol in Cardiovascular Disease Risk Prediction Models
David Faeh, MD, MPH; Julia Braun, MSc; Matthias Bopp, PhD, MPH
Arch Intern Med. 2012;172(22):1766-1768. doi:10.1001/2013.jamainternmed.327.
INCLUDES: , Supplemental Content
Editor's Correspondence |  October 22, 2012
What Is More Valuable: Fenofibrate Patents or Fenofibrate Clinical Outcomes?
Joel W. Hay, PhD
Arch Intern Med. 2012;172(19):1521-1522. doi:10.1001/archinternmed.2012.4386.
Original Investigation |  October 08, 2012
Comparative Effectiveness of 2 β-Blockers in Hypertensive Patients
Emily D. Parker, MPH, PhD; Karen L. Margolis, MD, MPH; Nicole K. Trower, BS; et al.
Arch Intern Med. 2012;172(18):1406-1412. doi:10.1001/archinternmed.2012.4276.
Invited Commentary |  October 08, 2012
Observational Comparative Effectiveness Studies of Drug Therapies:  High-Quality Answers or Important Clinical Questions?
Comment on “Comparative Effectiveness of 2 β-Blockers in Hypertensive Patients”
James S. Floyd, MD, MS; Bruce M. Psaty, MD, PhD
Arch Intern Med. 2012;172(18):1412-1414. doi:10.1001/archinternmed.2012.4306.
Invited Commentary |  October 08, 2012
Perfluorooctanoic Acid Exposure and Cardiovascular Disease:  Potential Role and Preventive Measures
Comment on “Perfluorooctanoic Acid and Cardiovascular Disease in US Adults”
Debabrata Mukherjee, MD, MS
Arch Intern Med. 2012;172(18):1403-1405. doi:10.1001/archinternmed.2012.3397.
Editor's Correspondence |  September 24, 2012
Raise the Bar Even Higher for Primary Prevention Interventions
James M. Wright, MD, PhD, CRCP(C); Ken L. Bassett, MD, PhD; Aaron M. Tejani, BSc(Pharm), PharmD
Arch Intern Med. 2012;172(17):1352-1353. doi:10.1001/archinternmed.2012.3723.
Editor's Correspondence |  September 24, 2012
Raise the Bar Even Higher for Primary Prevention Interventions—Reply
Vinay Prasad, MD; Andrae Vandross, MD
Arch Intern Med. 2012;172(17):1352-1353. doi:10.1001/archinternmed.2012.3963.
Research Letters |  September 24, 2012
Missed Opportunities for Treatment of Uncontrolled Hypertension at Physician Office Visits in the United States, 2005 Through 2009
Raman Ravi Khanna, MD, MAS; Ronald G. Victor, MD; Kirsten Bibbins-Domingo, PhD, MD; et al.
Arch Intern Med. 2012;172(17):1344-1345. doi:10.1001/archinternmed.2012.2749.
INCLUDES: , Supplemental Content
Review Article |  September 24, 2012
Physical Activity and Mortality in Individuals With Diabetes Mellitus:  A Prospective Study and Meta-analysis
Diewertje Sluik, MSc; Brian Buijsse, PhD; Rebecca Muckelbauer, PhD; et al.
Arch Intern Med. 2012;172(17):1285-1295. doi:10.1001/archinternmed.2012.3130.
INCLUDES: , Supplemental Content
Review Article |  September 24, 2012
Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus:  Systematic Review and Meta-analysis
Kerry McBrien, MD, MPH; Doreen M. Rabi, MD, MS; Norm Campbell, MD; et al.
Arch Intern Med. 2012;172(17):1296-1303. doi:10.1001/archinternmed.2012.3147.
INCLUDES: , Supplemental Content
Invited Commentary |  September 24, 2012
Use of a Single Target Blood Pressure Level in Type 2 Diabetes Mellitus for All Cardiovascular Risk Reduction:  Comment on “Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus”
Pantelis A. Sarafidis, MD, MSc, PhD; George L. Bakris, MD
Arch Intern Med. 2012;172(17):1304-1305. doi:10.1001/archinternmed.2012.4020.

Sign In

Register for a FREE personal account

and access these and other features:

Register Now

Want to Subscribe?

Learn More about subscription options.

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

From The JAMA Network
JAMA
Original Contribution  |  May 15, 2013
Association of Single- vs Dual-Chamber ICDs With Mortality, Readmissions, and Complications Among Patients Receiving an ICD for Primary Prevention
Pamela N. Peterson, MD, MSPH; Paul D. Varosy, MD; Paul A. Heidenreich, MD; et al.
JAMA
Original Contribution  |  May 08, 2013
Effect of Long-Detection Interval vs Standard-Detection Interval for Implantable Cardioverter-Defibrillators on Antitachycardia Pacing and Shock Delivery:  The ADVANCE III Randomized Clinical Trial
Maurizio Gasparini, MD; Alessandro Proclemer, MD; Catherine Klersy, MD, MSc; et al.
JAMA
Viewpoint  |  March 25, 2013
Combination Therapy to Prevent Cardiovascular Disease:  Slow Progress
Richard Smith, MB, ChB, MSc, FRCPE; Tara McCready, MBA, PhD; Salim Yusuf, DPhil, FRCPC, FRSC
JAMA
Original Contribution  |  April 17, 2013
Prevalence of a Healthy Lifestyle Among Individuals With Cardiovascular Disease in High-, Middle- and Low-Income Countries:  The Prospective Urban Rural Epidemiology (PURE) Study
Koon Teo, MB, PhD; Scott Lear, PhD; Shofiqul Islam, MSc; et al.
© 2013 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems